Recon: Japan approves Lilly’s Alzheimer’s drug; MHRA seeks applicants for AI Airlock

• Sanders says PBMs won’t penalize Novo for cutting Ozempic, Wegovy prices (STAT) (Reuters)
• The U.S. has relied on cheap, effective generic drugs for 40 years. Now that promise is under threat (STAT)
• As Medicare spending on remote patient monitoring jumps, HHS watchdog warns of fraud, misuse (STAT)
• Updated: Gene therapy maker bluebird bio cuts costs again, lays off staff (Endpoints)
• House passes reauthorization of rare pediatric voucher program (Endpoints)
• J&J talc opponents decry bankruptcy as "deja vu all over again" (Reuters)

• Eli Lilly's Alzheimer's drug approved in Japan (Reuters)
• Sanofi gets two bids valuing its consumer health unit at about $17 billion, Bloomberg News reports (Reuters)
• US to donate 1 million mpox vaccine doses to halt outbreak in Africa (Reuters)
• Child in UK 'defies odds' to survive withdrawal of life-sustaining treatment (Reuters)
• Angiodynamics Initiates Thrombectomy Trial In Europe After Showing Positive Trial Results in US (MedTech Insight)
• EU HTA Regulation: Some Member States Could Be ‘Deselected’ From Joint Assessments (Pink Sheet)
• Tech Vs Trialists: The Struggle For Integrated Decentralized Clinical Trial Platforms (Pink Sheet)
• MHRA opens applications from AI developers to join the AI Airlock regulatory sandbox (MHRA)

• Amid push to redefine itself, Sanofi names new chief scientific officer (STAT)
• Biogen-UCB's lupus drug meets main goal of late-stage trial (Reuters)
• Metsera’s GLP-1 drug has potential for monthly dosing, new data show (STAT)
• Regeneron’s Eylea biosimilar fight heats up (STAT)
• Wave rides new Phase 2 DMD data as it sets sights on accelerated approval (Endpoints)
• Drug delivery CDMO earmarks $356M to expand injectable device capacity (Endpoints)
• Samsara adds three venture partners to help steer and advise portfolio companies (Endpoints)
• Health plan startup Centivo raises $75M (Endpoints)
• Capricor to begin filing DMD drug with FDA next month; Surrozen’s $10M milestone (Endpoints)
• Zevra Therapeutics prices rare genetic disorder drug at up to $106,000 per month (Reuters)

• Most cardiovascular devices with serious safety recalls aren’t tested in patients (STAT)
• Electronic health records giant Epic Systems sued over alleged monopolistic practices (STAT)
• Route 92 Medical raises $50M to fund global sales of stroke devices (MedTech Dive)
• UK Medtechs Rue Low Cap Of Rules-Based Innovation Adoption Plan, Note AI Airlock Progress (MedTech Insight)
• J&J MedTech Keeps Up Cardiovascular Momentum With Shockwave E8 Launch In US (MedTech Insight)
• ‘Glass Cockpit Project’ Model For Home-Use Devices, Califf Says (MedTech Insight)

• Millions of people are missing from U.S. disability data (STAT)
• Will prescription drugs get prior authorization reform? (STAT)
• Lawmakers push to let telehealth providers keep prescribing stimulants and addiction treatment (STAT)
• KKR, GIC hire banks to sell stakes in $3.2 bln Metro Pacific Health, sources say (Reuters)
• Amneal asks court to block Colorado's free allergy pen program (Reuters)